

Patient Name

Patient Number

DOB

Consultant

Kent & Medway SACT proforma

MPV (sub cut - weekly)

Myeloma

Complete/ Partial Remission

Cycle No.....
(Repeat every 35 days)
Maximum 12 Cycles

Date Calculated →

Height (m)

Weight (kg)

Surface Area (m²)

Protocol Number
HAEM-MYEL-032

Authorising Consultant:
R Gate / *M Aldouri*

Pharmacist:
J. Sawyer/O. Okuwa
Review by December 2018
Version 1

Allergies:

- FBC before each dose of Bortezomib, U&Es and LFTs before each cycle.
- Haematological - Treat when neutrophils $\geq 1.0 \times 10^9/L$ and platelets $> 70 \times 10^9/L$ precycle & if neutrophils $\geq 0.75 \times 10^9/L$ or platelets $\geq 30 \times 10^9/L$ on a bortezomib dosing day. Reduce the Bortezomib dose (from 1.3 to 1.0 mg/m^2 or from 1.0 to 0.7 mg/m^2) if ≥ 2 doses have to be missed in a cycle. If neutrophils $< 0.5 \times 10^9/L$ or platelets $< 25 \times 10^9/L$ during cycle then consider a dose reduction of Melphalan to 75%.
- Hepatic – if bilirubin $1.5 - 3 \times \text{ULN}$ or $> 3 \times \text{ULN}$ Bortezomib – 0.7 mg/m^2 in first treatment cycle. Consider dose escalation to 1.0 mg/m^2 or further reduction to 0.5 mg/m^2 in subsequent cycles. Base on tolerability.
- Renal - Melphalan: CrCl 30-50ml/min give 50%; CrCl $< 30 \text{ ml/min}$ – clinical decision. Bortezomib: CrCl $< 20 \text{ ml/min}$ monitor for toxicities, consider dose reduction.
- Non-haematological - Grade 3 (inc. aesthetic condition, fatigue, malaise, weakness) withhold Bortezomib. Once toxicity resolved reinstitute at 75%.
- Neurotoxicity - Grade 2 (or grade 1 with pain) reduce dose to $1 \text{ mg/m}^2/\text{dose}$. Grade 3 (or grade 2 with pain) withhold until toxicity resolves, re-start at $0.7 \text{ mg/m}^2/\text{dose}$. Grade 4 Discontinue treatment.
- At least 72 hours must elapse between consecutive Bortezomib doses.
- Consider PCP prophylaxis/ antiviral/ antifungal therapy if lymphocyte count $< 1.0 \times 10^9/L$

Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Nurses Signature	Start Time	Stop Time
Day 1 .../.../...	BORTEZOMIB	1.3mg/m²	Sub cut						

Prescriber's Signature & Date:

Day 1 :

Pharmacist's Clinical Screen & Date:

Day 1 :

Final release signature & Date:

Day 1 :

Kent & Medway SACT proforma

MPV (sub cut - weekly)

Myeloma

Complete/ Partial Remission

Cycle No.....

(Repeat every 35 days)

Maximum 12 Cycles

Date Calculated →

Protocol Number
HAEM-MYEL-032

Height (m)

Authorising Consultant:
R Gale/ M Aldouri

Weight (kg)

Pharmacist:
J. Sawyer/O. Okuwa
Review by December 2018
Version 1

Surface Area (m²)

Allergies:

Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Nurses Signature	Start Time	Stop Time
Day 8 .../.../...	BORTEZOMIB 1.3mg/m²		Sub cut						
Day 15 .../.../...	BORTEZOMIB 1.3mg/m²		Sub cut						
Day 22 .../.../...	BORTEZOMIB 1.3mg/m²		Sub cut						

Prescriber's Signature & Date:

Day 8 :
Day 15 :
Day 22 :


Pharmacist's Clinical Screen & Date:

Day 8 :
Day 15 :
Day 22 :

Final release signature & Date:

Day 8 :
Day 15 :
Day 22 :

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.

Patient Name		Kent & Medway SACT proforma MPV (sub cut - weekly) Myeloma				Date Calculated →		Protocol Number HAEM-MYEL-032	
Patient Number						Height (m)		Authorising Consultant: R Galper M Aldouri 	
DOB		Complete/ Partial Remission Cycle No..... (Repeat every 35 days) Maximum 12 Cycles				Weight (kg)		Pharmacist: J. Sawyer/O. Okuwa Review by December 2018 Version 1	
Consultant						Surface Area (m ²)		Allergies:	
Notes									
TTO MEDICATION		Drug	Dose	Route	Directions	Date	Quantity	Disp	Check
		MELPHALAN 7mg/m ²		po	od days 1 - 4				
		PREDNISOLONE 60mg/m ²		po	om days 1 - 4				
		Allopurinol	300mg	po	Od for 7 days on cycle 1 only.				
		Aciclovir	400mg	po	bd				
		Ranitidine	150mg	po	bd Day 1-6 whilst on Prednisolone.				
Prescriber's Signature & Date:					Pharmacist's Clinical Screen & Date:		Final release signature & Date:		Page 3 of 3

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.